iSpecimen Inc Dossier
|
SectorHealth Care IndustryHealth Care Technology Beta (adjusted)1.42 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $1.18Price as of 30 Sep 2026 Data confidenceNot applicable Market Cap $3M Enterprise Value −$3.9M Shares Outstanding 2.5M diluted All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary iSpecimen Inc. is facing severe operational and financial distress. The company's core biospecimen marketplace business has experienced extreme revenue attrition, with Q1 2026 revenue plummeting 85% year-over-year to just $156,009. Despite aggressive cost-cutting measures—including reducing headcount to seven employees and slashing compensation and technology costs—the company continues to burn cash rapidly, reporting a net loss of $2.28 million for Q1 2026. With a working capital deficit of $2.12 million, an accumulated deficit of $84.63 million, and stockholders' equity of only $814,038, there is substantial doubt about the company's ability to continue as a going concern. Furthermore, iSpecimen is in non-compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million, posing an imminent delisting risk. While the company has implemented a 1-for-40 reverse stock split to maintain its bid price and raised nominal capital through private placements, the high risk of bankruptcy and severe dilution make the stock highly speculative and a candidate for a Strong Sell. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $0.2730% The company fails to regain compliance with Nasdaq's stockholders' equity requirement and is delisted to the OTC markets. Liquidity completely dries up, cost-cutting measures fail to stem the cash burn, and the company is forced to file for bankruptcy or liquidate its assets. Base CaseCentral scenario $1.4560% iSpecimen continues to operate with a highly downsized team, struggling to rebuild its revenue pipeline. It submits a compliance plan to Nasdaq but faces ongoing liquidity constraints, requiring highly dilutive equity raises to fund operations, which keeps the stock under severe downward pressure. Bull CaseUpside scenario $5.5010% The company successfully stabilizes its marketplace platform, leverages its newly launched AI-driven biospecimen matching agent to accelerate transaction volumes, and secures a strategic partnership or acquisition by a larger life sciences data firm looking to acquire its database of 19 million patient records. Scenarios reflect our research view at the research date. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |